Advanced Asset Management Advisors Inc acquired a new stake in Eli Lilly And Co (NYSE:LLY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,266 shares of the company’s stock, valued at approximately $378,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Ironwood Financial llc acquired a new stake in Eli Lilly And Co in the 4th quarter valued at about $30,000. Csenge Advisory Group acquired a new stake in Eli Lilly And Co in the 3rd quarter valued at about $58,000. Cornerstone Advisors Inc. lifted its stake in Eli Lilly And Co by 21.3% in the 3rd quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock valued at $83,000 after purchasing an additional 136 shares during the last quarter. Atwood & Palmer Inc. lifted its stake in Eli Lilly And Co by 267.0% in the 4th quarter. Atwood & Palmer Inc. now owns 734 shares of the company’s stock valued at $85,000 after purchasing an additional 534 shares during the last quarter. Finally, First Command Bank lifted its stake in Eli Lilly And Co by 31.3% in the 4th quarter. First Command Bank now owns 834 shares of the company’s stock valued at $96,000 after purchasing an additional 199 shares during the last quarter. Institutional investors own 80.84% of the company’s stock.
Shares of LLY stock opened at $119.65 on Thursday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. The company has a market cap of $125.67 billion, a price-to-earnings ratio of 21.56, a P/E/G ratio of 1.91 and a beta of 0.37. Eli Lilly And Co has a 12-month low of $74.51 and a 12-month high of $121.84.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The company had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 42.55% and a net margin of 13.16%. The company’s revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business earned $1.14 earnings per share. On average, sell-side analysts anticipate that Eli Lilly And Co will post 5.6 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a dividend of $0.645 per share. The ex-dividend date is Thursday, February 14th. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 annualized dividend and a yield of 2.16%. Eli Lilly And Co’s dividend payout ratio (DPR) is 40.54%.
In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly And Co stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $113.74, for a total value of $22,748,000.00. Following the completion of the sale, the insider now directly owns 118,600,804 shares in the company, valued at $13,489,655,446.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 4,000 shares of Eli Lilly And Co stock in a transaction that occurred on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The disclosure for this sale can be found here. Insiders have sold 817,843 shares of company stock valued at $94,595,335 over the last 90 days. Company insiders own 0.11% of the company’s stock.
Several equities research analysts recently issued reports on LLY shares. UBS Group cut their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research note on Friday, February 8th. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday, November 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $128.00 target price on shares of Eli Lilly And Co in a research note on Wednesday, October 17th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a research note on Wednesday, November 28th. Finally, ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. Eleven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co currently has an average rating of “Buy” and a consensus price target of $111.41.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: How Short Selling Works
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.